The insider buy is a small positive signal but not material. The key catalyst remains the Phase 3 trial initiation for urcosimod in H2 2026. Monitor for trial enrollment updates and any financing needs given the shelf registration on file.
Price Chart
Executive Summary
OKYO Pharma disclosed via 6-K that Chief Development Officer and Director Gary S. Jacob purchased 3,500 ordinary shares on Nasdaq at $1.40 per share, increasing his total holdings to 112,420 shares. This insider open-market buy is a modest positive signal of alignment, but the $4,900 total value is trivial relative to the $49M market cap. The filing also reiterates plans to initiate a global Phase 3 trial for urcosimod in NCP in H2 2026, which is the primary catalyst. The 20-F annual report filed 2 days ago provides the financial context for this clinical-stage biotech with no approved products.
Key Facts
- Gary S. Jacob, Chief Development Officer and Director, purchased 3,500 ordinary shares at $1.40/share on July 22, 2026.
- Total holdings increased to 112,420 ordinary shares.
- Purchase value is approximately $4,900, a trivial amount relative to the ~$49M market cap.
- Company plans to initiate a global Phase 3 pivotal trial for urcosimod (NCP) in H2 2026, enrolling ~111 patients.
- Filing is incorporated by reference into the Company's Form F-3 shelf registration (Reg. No. 333-293145).
Financial Impact
Insider purchase of $4,900 at $1.40/share — negligible financial impact.
Risk Factors
- Clinical-stage biotech with no approved products or revenue — binary Phase 3 risk.
- Cash runway and potential dilution from the existing F-3 shelf registration are key concerns.
- Historical stock performance shows negative drift post-filing for this ticker.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 10 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (OKYO) — Batch item 1 | 0001493152-26-034197 |
| Exhibit: ex99-1.htm | 0001493152-26-034197 |
| Document: 0001493152-26-034197-index-headers.html | 0001493152-26-034197 |
| Document: 0001493152-26-034197-index.html | 0001493152-26-034197 |
| Document: 0001493152-26-034197.txt | 0001493152-26-034197 |
| 6-K Filing (OKYO) — Batch item 6 | 0001493152-26-034197 |
| Exhibit: ex99-1.htm | 0001493152-26-034197 |
| Document: 0001493152-26-034197-index-headers.html | 0001493152-26-034197 |
| Document: 0001493152-26-034197-index.html | 0001493152-26-034197 |
| Document: 0001493152-26-034197.txt | 0001493152-26-034197 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | 6-K | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.42 (−2.77%) |
Oct 6, 2026 21d ago | Press Release | $1.46 $1.41 | ▼ −3.42% | ▼ −3.18% | $1.42 (−2.77%) |
Sep 29, 2026 28d ago | 6-K | $1.36 $1.29 | ▼ −5.15% | ▼ −4.94% | $1.42 (+4.37%) |
Sep 8, 2026 7w ago | 6-K | $1.53 $1.45 | ▼ −5.23% | ▼ −4.76% | $1.42 (−7.22%) |
Aug 7, 2026 11w ago | Insider Cluster | $1.57 $1.52 | ▼ −3.18% | ▼ −2.87% | $1.42 (−9.59%) |
Jul 28, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▲ +1.54% | $1.42 (−13.45%) |
Jul 27, 2026 13w ago | 6-K | $1.64 $1.64 | · 0.00% | ▼ −0.24% | $1.42 (−13.45%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.42 (−4.09%) |
Jul 23, 2026 13w ago | Press Release | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.42 (−4.09%) |
Jul 23, 2026 13w ago | 6-K | $1.48 $1.55 | ▲ +4.73% | ▲ +4.63% | $1.42 (−4.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers